相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data
Susan E. Bates et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Mitosis, microtubule dynamics and the evolution of kinesins
Juan Jesus Vicente et al.
EXPERIMENTAL CELL RESEARCH (2015)
Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial
Jean-Yves Blay et al.
LANCET ONCOLOGY (2015)
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics
Stefan Vallo et al.
TRANSLATIONAL ONCOLOGY (2015)
Pseudolaric Acid B Circumvents Multidrug Resistance Phenotype in Human Gastric Cancer SGC7901/ADR Cells by Downregulating Cox-2 and P-gp Expression
Fei Yu et al.
CELL BIOCHEMISTRY AND BIOPHYSICS (2015)
The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments
Cassandra D. M. Churchill et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2015)
Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells
Marc St George et al.
PLOS ONE (2015)
Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A
Andrea E. Prota et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
Microtubule-targeting Anticancer Agents from Marine Natural Substance
Zhiguo Liu et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2014)
Development of other microtubule-stabilizer families: the epothilones and their derivatives
Cynthia F. Brogdon et al.
ANTI-CANCER DRUGS (2014)
Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function
Jessica J. Field et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Synthesis and Cytotoxic Activity of 2-Anilinopyridine-3-Acrylamides as Tubulin Polymerization Inhibitors
Ahmed Kamal et al.
CHEMMEDCHEM (2014)
Tubulin inhibitors: a patent review
Yi-Min Liu et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2014)
Fosbretabulin for the treatment of anaplastic thyroid cancer
Roberta Granata et al.
FUTURE ONCOLOGY (2014)
Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents
Shilong Zheng et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Targeting Microtubules by Natural Agents for Cancer Therapy
Eiman Mukhtar et al.
MOLECULAR CANCER THERAPEUTICS (2014)
The Inhibitory Effect of Pseudolaric Acid B on Gastric Cancer and Multidrug Resistance via Cox-2/PKC-α/P-gp Pathway
Qian Sun et al.
PLOS ONE (2014)
A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs
Andrea E. Prota et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma
Julie A. Sosa et al.
THYROID (2014)
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy
Kelsey Klute et al.
ONCOTARGETS AND THERAPY (2014)
Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma
Herbert H. Loong et al.
ONCOTARGETS AND THERAPY (2014)
Microtubules and their role in cellular stress in cancer
Amelia L. Parker et al.
FRONTIERS IN ONCOLOGY (2014)
Vascular-disrupting agents in oncology
Monica M. Mita et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2013)
Recent approaches for the synthesis of modified cryptophycins
Christine Weiss et al.
NATURAL PRODUCT REPORTS (2013)
MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications
Kurt R. Brunden et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
J. Cummings et al.
BRITISH JOURNAL OF CANCER (2012)
Discovery of Small Molecule Inhibitors that Interact with γ-Tubulin
Douglas E. Friesen et al.
CHEMICAL BIOLOGY & DRUG DESIGN (2012)
Efficient, divergent synthesis of cryptophycin unit A analogues
Kyle L. Bolduc et al.
CHEMICAL COMMUNICATIONS (2012)
A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients
Tian Ma et al.
CHEMOTHERAPY (2012)
Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors
Dan M. Patterson et al.
CLINICAL CANCER RESEARCH (2012)
Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer
Marta De Donato et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2012)
The Vascular-Disrupting Agent Combretastatin Impairs Splitting and Sprouting Forms of Physiological Angiogenesis
Arif Hussain et al.
MICROCIRCULATION (2012)
Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B-Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos
Laura L. Vollmer et al.
MOLECULAR CANCER THERAPEUTICS (2011)
A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer
J. Michels et al.
ANNALS OF ONCOLOGY (2010)
βIII-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non-Small Cell Lung Cancer
Joshua A. McCarroll et al.
CANCER RESEARCH (2010)
Differential Expression and Cellular Distribution of γ-Tubulin and βIII-Tubulin in Medulloblastomas and Human Medulloblastoma Cell Lines
Valentina Caracciolo et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2010)
Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study
Koen De Geest et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of βIII-Tubulin
Pei Pei Gan et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Microtubule-binding agents: a dynamic field of cancer therapeutics
Charles Dumontet et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
Microtubules and resistance to tubulin-binding agents
Maria Kavallaris
NATURE REVIEWS CANCER (2010)
Increased γ-tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast
T. Liu et al.
ANNALS OF ONCOLOGY (2009)
Indibulin, a Novel Microtubule Inhibitor, Discriminates between Mature Neuronal and Nonneuronal Tubulin
Anke Wienecke et al.
CANCER RESEARCH (2009)
Microtubule dynamics as a target in oncology
April L. Risinger et al.
CANCER TREATMENT REVIEWS (2009)
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Dietmar W. Siemann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
AVE8062: a new combretastatin derivative vascular disrupting agent
Angelo Delmonte et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma
Richard L. Piekarz et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Intracellular Activation and Deactivation of Tasidotin, an Analog of Dolastatin 15: Correlation with Cytotoxicity
Ruoli Bai et al.
MOLECULAR PHARMACOLOGY (2009)
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer
J. Horti et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors
Elizabeth Fox et al.
CLINICAL CANCER RESEARCH (2008)
Phase II trial of T138067, a novel microtubule inhibitor, in patients with metastatic, refractory colorectal carcinoma
Jordan D. Berlin et al.
CLINICAL COLORECTAL CANCER (2008)
Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region
Giuseppina Raspaglio et al.
GENE (2008)
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M. Mauer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Ixabepilone: A novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms
Linda Vahdat
ONCOLOGIST (2008)
Preclinical analysis of tasidotin HCl in Ewing's sarcoma, rhabdomyosarcoma, synovial sarcoma, and osteosarcoma
Vaani Garg et al.
CLINICAL CANCER RESEARCH (2007)
Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative and inhibitor of tubulin polymerization, which was administered to patients with advanced solid tumors on days 1 and 8 in 3-week courses
Kenji Tamura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
I. E. L. M. Kuppens et al.
INVESTIGATIONAL NEW DRUGS (2007)
Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate
Anasuya Ray et al.
CANCER RESEARCH (2007)
Embellistatin, a microtubule polymerization inhibitor, inhibits angiogenesis both in vitro and in vivo
Hye Jin Jung et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2007)
A phase 2 study of TZT-1027, administered weekly to patients with advanced non-small cell lung cancer following treatment with platinum-based chemotherapy
Gregory J. Riely et al.
LUNG CANCER (2007)
Recent progress in discovery and development of antimitotic agents
Alex Kiselyov et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2007)
Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells
Ilio Vitale et al.
APOPTOSIS (2007)
Targeting the microtubules in breast cancer beyond taxanes: The epothilones
Javier Cortes et al.
ONCOLOGIST (2007)
Phase II study of intravenous TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas with prior exposure to anthracycline-based chemotherapy
Shreyaskumar Patel et al.
CANCER (2006)
Anti-vascular agent Combretastatin A-4-P modulates Hypoxia Inducible Factor-1 and gene expression
Gabi U. Dachs et al.
BMC CANCER (2006)
Synergistic effects of peloruside a and laulimalide with taxoid site drugs, but not with each other, on tubulin assembly
Ernest Hamel et al.
MOLECULAR PHARMACOLOGY (2006)
Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with advanced solid tumors
Alain C. Mita et al.
CLINICAL CANCER RESEARCH (2006)
Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death
Xianfeng Gong et al.
EXPERIMENTAL AND MOLECULAR MEDICINE (2006)
A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours
A. Greystoke et al.
ANNALS OF ONCOLOGY (2006)
Combretastatin A-1 phosphate potentiates the antitumor activity of carboplatin and paclitaxel in a severe combined immunodeficiency disease (SCID) mouse model of human ovarian carcinoma
K. Staflin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Altered cellular distribution and subcellular sorting of γ-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines
Christos D. Katsetos et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2006)
Pseudolarix acid B, a new tubulin-binding agent, inhibits angiogenesis by interacting with a novel binding site on tubulin
YG Tong et al.
MOLECULAR PHARMACOLOGY (2006)
The microtubule binding drug laulimalide inhibits vascular endothelial growth factor-induced human endothelial cell migration and is synergistic when combined with docetaxel taxotere)
HY Lu et al.
MOLECULAR PHARMACOLOGY (2006)
Total synthesis and biological evaluation of 11-desmethyllaulimalide, a highly potent simplified laulimalide analogue
PA Wender et al.
ORGANIC LETTERS (2006)
A multicenter phase II study of the cryptophycin analog LY355703 in patients with platinum-resistant ovarian cancer
G D'Agostino et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Epothilones in the treatment of cancer
James M. G. Larkin et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2006)
Tubulin assembly, taxoid site binding, and cellular effects of the microtubule-stabilizing agent dictyostatin
C Madiraju et al.
BIOCHEMISTRY (2005)
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling
L Vincent et al.
JOURNAL OF CLINICAL INVESTIGATION (2005)
A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors
S Ebbinghaus et al.
CLINICAL CANCER RESEARCH (2005)
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors
C Cunningham et al.
CLINICAL CANCER RESEARCH (2005)
In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models
JK Peterson et al.
CLINICAL CANCER RESEARCH (2005)
Phase II trials of dolastatin-10 in advanced pancreaticobiliary cancers
HL Kindler et al.
INVESTIGATIONAL NEW DRUGS (2005)
A phase I study of T900607 given once every 3 weeks in patients with advanced refractory cancers; National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) IND 130
KA Gelmon et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
KWL Yee et al.
CLINICAL CANCER RESEARCH (2005)
Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo
VKW Wong et al.
CLINICAL CANCER RESEARCH (2005)
A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence
CPH Yang et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Phase II trial of dolastatin-10 in patients with advanced breast cancer
EA Perez et al.
INVESTIGATIONAL NEW DRUGS (2005)
Cryptophycins-309, 249 and other cryptophycin analogs: Preclinical efficacy studies with mouse and human tumors
J Liang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Phase I and pharmacokinetic study of the dolastatin 10 analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors
MJA de Jonge et al.
CLINICAL CANCER RESEARCH (2005)
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada clinical trials group
S Kirby et al.
NEURO-ONCOLOGY (2005)
Phase I trial of combretastatin A-4 phosphate with carboplatin
JH Bilenker et al.
CLINICAL CANCER RESEARCH (2005)
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer
P Schöffski et al.
ANNALS OF ONCOLOGY (2004)
A kinesin-like motor inhibits microtubule dynamic instability
H Bringmann et al.
SCIENCE (2004)
Comparative preclinical pharmacokinetic and metabolic studies of the combretastatin prodrugs combretastatin A4 phosphate and A1 phosphate
IG Kirwan et al.
CLINICAL CANCER RESEARCH (2004)
Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect
WF Tan et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2004)
Combretastatin family member OXI4503 induces tumor vascular collapse through the induction of endothelial apoptosis
YZ Sheng et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
Combretastatin A4 phosphate: background and current clinical status
SL Young et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2004)
Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1α by promoting proteasome-mediated degradation
MH Li et al.
CLINICAL CANCER RESEARCH (2004)
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence
H Wildiers et al.
EUROPEAN JOURNAL OF CANCER (2004)
Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry
E Stokvis et al.
RAPID COMMUNICATIONS IN MASS SPECTROMETRY (2004)
Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer
MM Cooney et al.
CLINICAL CANCER RESEARCH (2004)
Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis
K Hori et al.
BRITISH JOURNAL OF CANCER (2003)
Dolastatin 15 binds in the vinca domain of tubulin as demonstrated by Hummel-Dreyer chromatography
Z Cruz-Monserrate et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Phase I clinical trial of weekly combretastatin A4 phosphate: Clinical and pharmacokinetic results
GJS Rustin et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A phase II study of the dolastatin 15 analogue LU 103793 in the treatment of advanced non-small-cell lung cancer
RS Marks et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2003)
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate
HL Anderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Pharmacokinetics and tissue distribution of cryptophycin 52 (C-52) epoxide and cryptophycin 55 (C-55) chlorohydrin in mice with subcutaneous tumors
RR Boinpally et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2003)
Class III β-tubulin in human development and cancer
CD Katsetos et al.
CELL MOTILITY AND THE CYTOSKELETON (2003)
(Z)-sarcodictyin A, a new highly cytotoxic diterpenoid from the soft coral Bellonella albiflora
Y Nakao et al.
JOURNAL OF NATURAL PRODUCTS (2003)
A phase II trial of dolastatin-10 in recurrent platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study
MA Hoffman et al.
GYNECOLOGIC ONCOLOGY (2003)
Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo
Y Morinaga et al.
CANCER SCIENCE (2003)
Phase II study of LU 103793 (dolastatin analogue) in patients with metastatic breast cancer
P Kerbrat et al.
EUROPEAN JOURNAL OF CANCER (2003)
Phase 2 study of cryptophycin 52 (LY355703) in patients previously treated with platinum based chemotherapy for advanced non-small cell lung cancer
MJ Edelman et al.
LUNG CANCER (2003)
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
JP Stevenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Phase I and pharmacological studies of the cryptophycin analogue LY355703 administered on a single intermittent or weekly schedule
C Sessa et al.
EUROPEAN JOURNAL OF CANCER (2002)
Combination of vascular targeting agents with thermal or radiation therapy
MR Horsman et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
The development of combretastatin A4 phosphate as a vascular targeting agent
DJ Chaplin et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models
SA Hill et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Phase II study of dolastatin-10 as first-line treatment for advanced colorectal cancer
ED Saad et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2002)
The microtubule stabilizing agent laulimalide does not bind in the taxoid site, kills cells resistant to paclitaxel and epothilones, and may not require its epoxide moiety for activity
DE Pryor et al.
BIOCHEMISTRY (2002)
The tumor vascular targeting agent combretastatin A-4-phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells
C Kanthou et al.
BLOOD (2002)
The biology of the combretastatins as tumour vascular targeting agents
GM Tozer et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2002)
A phase II study of CI-980 in previously untreated extensive small cell lung cancer: An Ohio State University Phase II Research Consortium study
JP Thomas et al.
CANCER INVESTIGATION (2002)
Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma
L Li et al.
ACTA ONCOLOGICA (2002)
Anticancer therapy with novel tubulin-interacting drugs
M Kavallaris et al.
DRUG RESISTANCE UPDATES (2001)
Hydrophilic, pro-drug analogues of T138067 are efficacious in controlling tumor growth in vivo and show a decreased ability to cross the blood brain barrier
SM Rubenstein et al.
JOURNAL OF MEDICINAL CHEMISTRY (2001)
Cryptophycins: A novel class of potent antimitotic antitumor depsipeptides
C Shih et al.
CURRENT PHARMACEUTICAL DESIGN (2001)
Activity of the dolastatin analogue, LU103793, in malignant melanoma
J Smyth et al.
ANNALS OF ONCOLOGY (2001)
Targeting tumour vasculature: the development of combretastatin A4
Jeremy Griggs et al.
LANCET ONCOLOGY (2001)
Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor
Y Funahashi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)
Dolastatin-10 in metastatic melanoma: A phase II and pharmokinetic trial of the california cancer consortium
K Margolin et al.
INVESTIGATIONAL NEW DRUGS (2001)
Synthesis and biological evaluation of highly potent analogues of epothilones B and D
KH Altmann et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2000)
Interaction of the antitumor compound cryptophycin-52 with tubulin
D Panda et al.
BIOCHEMISTRY (2000)
Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent
J Watanabe et al.
APOPTOSIS (2000)
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion
JG Supko et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Antitumor activity of cryptophycins: effect of infusion time and combination studies
K Menon et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2000)
Phase II study of dolastatin-10 in patients with advanced non-small-cell lung cancer
LM Krug et al.
ANNALS OF ONCOLOGY (2000)
Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas
W Landuyt et al.
EUROPEAN JOURNAL OF CANCER (2000)
A phase I study of rhizoxin (NSC 332598) by 72-hour continuous intravenous infusion in patients with advanced solid tumors
AW Tolcher et al.
ANNALS OF ONCOLOGY (2000)
分享论文
